About: Why Do We Need Another Antiemetic? Just Ask

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Why Do We Need Another Antiemetic? Just Ask Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 October 2003

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2003 (uk) im November 2003 veröffentlichter wissenschaftlicher Artikel (de) article scientifique publié en 2003 (fr) scientific article published on 14 October 2003 (en) artículu científicu espublizáu n'ochobre de 2003 (ast)
publication date	wds:Q59566139-A604C461-1468-4659-A5C1-D1F1922C64C8
publication date	2003-10-14 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59566139-A3B613AB-587E-4EF3-83FE-460350CABA83
language of work or name	English
author name string	wds:Q59566139-7A2C2EE1-55C0-46F1-AD09-FBA033717049
author name string	Mark G. Kris
rdfs:label	Why Do We Need Another Antiemetic? Just Ask (en) Why Do We Need Another Antiemetic? Just Ask (nl)
skos:prefLabel	Why Do We Need Another Antiemetic? Just Ask (en) Why Do We Need Another Antiemetic? Just Ask (nl)
name	Why Do We Need Another Antiemetic? Just Ask (en) Why Do We Need Another Antiemetic? Just Ask (nl)
author	wds:Q59566139-01A8F0B5-BA0F-411B-BB7D-479858D13095
author	Mark G Kris
title	wds:Q59566139-EABC9A15-30CA-46C5-BD22-C65B7CBCDDA5
title	Why do we need another antiemetic? Just ask (en)
page(s)	wds:Q59566139-64D22CB9-696F-4761-8D6B-2194B330492B
page(s)	4077-4080
instance of	wds:Q59566139-B43DDF15-9212-43B4-B135-0A7058D94B9C
instance of	scholarly article
PubMed ID	wds:Q59566139-A6FFB2CB-EB6E-417F-8FF1-18D655202514
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14559888
PubMed ID	14559888
published in	wds:Q59566139-C0AA7188-1DC3-4238-B2DC-5D91D16B7DF8
published in	Journal of Clinical Oncology
issue	wds:Q59566139-DBB8C7D7-CD29-45AF-8DB2-57BDB8196EEC
volume	wds:Q59566139-AB552BAF-43B9-4A03-8A1D-FB15162B30E0
issue	22
volume	21
DOI	wds:Q59566139-9538F798-C2CE-4C31-8BB8-6447B734C761
DOI	http://dx.doi.org/10.1200/JCO.2003.07.968
DOI	10.1200/JCO.2003.07.968
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59566139
is cites work of	Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
is cites work of	wds:Q26784070-5ADE1DB7-9D4E-458B-A57C-CB17273E16FD wds:Q45256831-2B8DEA9C-865C-4007-A3F7-5C2EDF63098A wds:Q37445006-7DD05D15-D670-41FF-86BD-A077E3CF661B wds:Q34327488-2C825D30-91FC-4BD1-96E1-3C39CFB0F28E wds:Q35056522-C053681F-F598-4B23-BA14-A534B5920A3E wds:Q37091366-DBC75A97-104A-4CD7-8BD9-F7BF9CC15A4F wds:Q34647257-6989FB3D-C42C-43DC-99D0-BABFB1033C18 wds:Q30973575-1945D8BB-8C80-4C1D-8678-2869F7C8F3D8 wds:Q80475296-80C8B4B6-511D-43AD-9064-1E058D37246E wds:Q30992721-EF051087-634F-4259-9073-4BC0CEF04073 wds:Q35693273-1EA2C565-1683-4E0D-9286-55499AF65020 wds:Q46848063-2F47816C-E1E8-469B-8C3B-BCAAD4E12DFD wds:Q81657400-6FF10538-CD2F-4568-B861-A7AB08DDA229

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software